NCT07345364
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Participants
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 5 more changesShow less
- Trial completed
- Final enrollment: 64 participants (planned 72)
- Primary completion date changed from estimate of Jul 30, 2026 to Jun 18, 2026
- Secondary endpoints: details revised at 1 of 4 entries
- Site details revised
Notable Recruitment openedv2 Show 7 more changesShow less
- Eligibility criteria revised
- Primary completion pushed from Jun 30, 2026 to Jul 30, 2026
- Enrollment increased: 56 → 72 participants
- Study completion pushed from Jul 31, 2026 to Aug 31, 2026
- Start date changed from estimate of Jan 13, 2026 to Jan 12, 2026
- Site details revised
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
The study is designed to include 6 dose groups across 9 cohorts, with two administration methods: intravenous bolus plus intravenous infusion, and intravenous bolus alone. Each cohort will enroll 6 participants to receive SIM0811 The study will employ a dose-escalation design starting from Cohort 1. After administration in each dose group/cohort, participants will be observed for 7 days for safety evaluation. Provided no stopping criteria are met, escalation to the next dose level may proceed only after review by the Safety Review Committee (SRC)
The study is designed to include 7 dose groups across 9 cohorts, with two administration methods: intravenous bolus plus intravenous infusion, and intravenous bolus alone. Each cohort will enroll 2 participants to receive placebo The study will employ a dose-escalation design starting from Cohort 1. After administration in each dose group/cohort, participants will be observed for 7 days for safety evaluation. Provided no stopping criteria are met, escalation to the next dose level may proceed only after review by the Safety Review Committee (SRC)
Drugs: SIM0811, Placebo
Sites
1 site in 1 country
- Qilu Hospital of Shandong UniversityJinan, Shandong, China